# Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?

> **NCT04665375** · PHASE4 · TERMINATED · sponsor: **University Health Network, Toronto** · enrollment: 4 (actual)

## Conditions studied

- Hiv
- Weight Gain

## Interventions

- **DRUG:** DOR/3TC/TDF

## Key facts

- **NCT ID:** NCT04665375
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-26
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** enrollment futility
- **Last updated:** 2025-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04665375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04665375, "Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04665375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*